Butyrylcholinesterase and cognitive function

International Psychogeriatrics

Volumn 13, Issue 4, 2001, Pages 461-464

  Darvesh, Sultan ^a   MacKnight, Chris ^a   Rockwood, Kenneth ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Alzheimer; Cholinesterase; Ethopropazine

Indexed keywords

CHLORPROMAZINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; PROFENAMINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; DISEASE COURSE; DOSE RESPONSE; HUMAN; MALE; SCHIZOPHRENIA;

ADULT; BRAIN; BUTYRYLCHOLINESTERASE; CHLORPROMAZINE; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; HUMANS; MALE; NEURONS; PHENOTHIAZINES; SCHIZOPHRENIA;

EID: 0035734637     PISSN: 10416102     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1041610201007876     Document Type: Article

References (12)

1. Ethopropazine and benztropine in neuroleptic-induced parkinsonism
2. Butyrylcholinesterase in normal human amygdala and hippocampal formation
3. Distribution of butyrylcholinesterase in normal human forebrain
4. Systemic therapy of dystonia
5. The cholinergic hypothesis of Alzheimer's disease: A review of progress
6. Anti-nicotinic properties of anticholinergic antiparkinson drugs
7. Cholinesterase inhibitors: From calabar bean to Alzheimer therapy
8. Novel, selective butyrylcholinesterase (BuChE) inhibitors for the treatment of Alzheimer's disease (AD)
9. Effects of anticholinergic antiparkinsonian drugs on binding of muscarinic receptor subtypes in rat brain
10. Neuroanatomy of cholinesterases in the normal human brain and Alzheimer's disease
11. Subnucleus-specific loss of neurons in medial thalamus of schizophrenics